{"schema_version":"secwatch.filing_event.v1","accession":"0001048477-25-000049","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.309049+00:00","generated_at":"2026-05-22T23:38:50.594847+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BioMarin Q1 2025 revenue $745M (+15% YoY), GAAP EPS $0.95, reaffirms 2025 guidance","bullets":["Q1 total revenues $745M (+15% Y/Y); GAAP net income $186M (+109% Y/Y); non-GAAP income $221M (+58% Y/Y).","VOXZOGO revenue $214M (+40% Y/Y) driven by global demand; Enzyme Therapies revenue $484M (+8% Y/Y) led by PALYNZIQ (+22% Y/Y).","GAAP diluted EPS $0.95 (+107% Y/Y); non-GAAP diluted EPS $1.13 (+59% Y/Y). Operating margin expanded 16.4 ppt GAAP, 11.9 ppt non-GAAP.","Reaffirmed full-year 2025 financial guidance; notes immaterial tariff exposure from enacted tariffs.","Pipeline: VOXZOGO pivotal hypochondroplasia study fully enrolled; BMN 333 plan agreed with FDA; PALYNZIQ adolescent study met primary endpoint."],"urls":{"canonical":"https://secwatch.observer/filing/0001048477-25-000049","json":"https://secwatch.observer/filing/0001048477-25-000049.json","markdown":"https://secwatch.observer/filing/0001048477-25-000049.md","text":"https://secwatch.observer/filing/0001048477-25-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000104847725000049/0001048477-25-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000104847725000049/bmrn-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T23:38:50.594847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}